Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Rhea-AI Summary
Zevra Therapeutics (NASDAQ: ZVRA) said its executive leadership will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 15, 2026 at 9:45 a.m. PT. Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations "Events & Presentations" page at investors.zevra.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ZVRA gained 1.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Ahead of the J.P. Morgan conference, ZVRA was up 2.05%. In the momentum scanner, peer ERAS appeared with a sharp −11.99% move, while no other close peers were flagged, suggesting the setup looked company-specific rather than a broad biotechnology move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Access agreement | Positive | -0.6% | Exclusive MIPLYFFA access deal with Uniphar for select ex-Europe territories. |
| Dec 12 | Inducement grants | Neutral | -1.9% | Stock option grants to new employees under inducement award plan. |
| Dec 02 | Board change | Neutral | -2.0% | Appointment of Alicia Secor and retirement of director Wendy Dixon. |
| Nov 20 | CFO transition | Negative | -6.5% | Announcement of CFO R. LaDuane Clifton’s planned resignation. |
| Nov 05 | Q3 2025 earnings | Positive | +2.9% | Strong revenue growth and sharply lower net loss for Q3 2025. |
Recent news skewed mildly positive or neutral, yet price often edged lower on those headlines, with only the strong Q3 2025 earnings showing a clear positive reaction.
Over the past few months, Zevra reported improving fundamentals and multiple corporate updates. Q3 2025 results on Nov 5 showed net revenue of $26.1M and a sharply reduced quarterly net loss, which saw the stock gain 2.86%. Subsequent items included a CFO transition on Nov 20 (stock down 6.51%), board changes on Dec 2, inducement grants on Dec 12, and a MIPLYFFA access agreement on Dec 29, each followed by modest declines. Today’s conference appearance fits into this cadence of ongoing corporate communications rather than a major new catalyst.
Market Pulse Summary
This announcement highlights Zevra’s participation in the J.P. Morgan Healthcare Conference on January 15, 2026, giving management a platform to discuss its rare‑disease portfolio and recent progress. Context includes strong Q3 2025 revenue of $26.1M, the MIPLYFFA access agreement announced on Dec 29, and recent leadership changes in the finance organization. Investors may watch for updated commentary on commercial performance, regulatory milestones, and capital allocation priorities during the conference webcast.
AI-generated analysis. Not financial advice.
CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) present at the J.P. Morgan Healthcare Conference?
How can investors watch the Zevra (ZVRA) presentation on January 15, 2026?
Will Zevra management be available for meetings at the J.P. Morgan 44th Annual Healthcare Conference?
What is the ticker symbol for Zevra Therapeutics referenced at the conference?
Where is the J.P. Morgan 44th Annual Healthcare Conference taking place for Zevra's presentation?
